The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Non-small Cell Lung Cancer
Related studies linked through entity extraction aliases.
A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
BESPOKE Study of ctDNA Guided Immunotherapy
- Status
- COMPLETED
- Phase
- N/A
FL-101 in Surgically Resectable Non-Small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer
- Status
- UNKNOWN
- Phase
- NA
Effect of Mirtazapine Versus Placebo in Patients With Non-small Cell Lung Cancer and Anorexia
- Status
- COMPLETED
- Phase
- NA
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Obstructive Sleep Apnea Influences Efficacy of PD-1-Based Immunotherapy Against Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- N/A
Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- N/A
Managed Access Programs for INC280, Capmatinib
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.
- Status
- UNKNOWN
- Phase
- N/A
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
- Status
- TERMINATED
- Phase
- N/A
M1231 in Participants With Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Gut Microbiota and Cancer Immunotherapy Response
- Status
- UNKNOWN
- Phase
- N/A
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3